Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.
1. An isolated double stranded nucleic acid (dsNA) comprising first and second nucleic acid strands and a duplex region of at least 25 base pairs, wherein each of said first and second nucleic acid strands comprises RNA and has a length which is at least 25 and at most 35 nucleotides, wherein said second oligonucleotide strand is perfectly complementary to SEQ ID NO: 4909 along at least 21 nucleotides of said second oligonucleotide strand length to reduce KRAS target gene expression when said double stranded nucleic acid is introduced into a mammalian cell.
2. The isolated dsNA of claim 1 , wherein the 3′ end of the first oligonucleotide strand and the 5′ end of the second oligonucleotide strand are linked by a chemical linker, extended loop or tetraloop.
3. The isolated dsNA of claim 1 , wherein said first strand is 25 nucleotides in length and said second strand is 27 nucleotides in length.
4. The isolated dsNA of claim 1 , wherein said second strand comprises SEQ ID NO: 4423.
5. The isolated dsNA of claim 1 , wherein said first strand comprises a sequence that is fully complementary to SEQ ID NO: 4423.
6. The isolated double-stranded nucleic acid of claim 1 , wherein said second strand of said dsNA comprises 1-5 single-stranded nucleotides at its 3′ terminus.
7. The isolated dsNA of claim 1 , wherein said dsNA comprises a modified nucleotide residue.
8. The isolated dsNA of claim 7 , wherein the modified nucleotide residue is selected from the group consisting of a deoxyribonucleotide, a dideoxyribonucleotide, an acyclonucleotide, a 3′-deoxyadenosine (cordycepin), a 3′-azido-3′-deoxythymidine (AZT), a 2′,3′-dideoxyinosine (ddI), a 2′,3′-dideoxy-3′-thiacytidine (3TC), a 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), a monophosphate nucleotide of 3′-azido-3′-deoxythymidine (AZT), a 2′,3′-dideoxy-3′-thiacytidine (3TC) and a monophosphate nucleotide of 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), a 4-thiouracil, a 5-bromouracil, a 5-iodouracil, a 5-(3-aminoallyl)-uracil, a 2′-O-alkyl ribonucleotide, a 2′-O-methyl ribonucleotide, a 2′-amino ribonucleotide, a 2′-fluoro ribonucleotide, a locked nucleic acid, 2′-methoxyethoxy, 2′-allyl, 2′-O-[2-(methylamino)-2-oxoethyl], 4′-thio, 4′-CH2-O-2′-bridge, 4′-(CH2)2-O-2′-bridge, and 2′-O—(N-methylcarbamate).
9. The isolated dsNA of claim 1 , wherein the amount of said isolated double stranded nucleic acid sufficient to reduce expression of the target gene is selected from the group consisting of 1 nanomolar or less, 200 picomolar or less, 100 picomolar or less, 50 picomolar or less, 20 picomolar or less, 10 picomolar or less, 5 picomolar or less, 2, picomolar or less and 1 picomolar or less in the environment of said cell.
10. The isolated double stranded nucleic acid of claim 1 comprising a phosphate backbone modification selected from the group consisting of a phosphonate, a phosphorothioate and a phosphotriester.
11. A composition possessing KRAS inhibitory activity consisting essentially of an isolated double stranded ribonucleic acid (dsNA) comprising first and second nucleic acid strands and a duplex region of at least 25 base pairs, wherein said second strand of said dsNA comprises 1-5 single-stranded nucleotides at its 3′ terminus, wherein said second oligonucleotide strand is perfectly complementary to SEQ ID NO: 4909 along at least 21 nucleotides of said second oligonucleotide strand length and said double stranded nucleic acid reduces KRAS target gene expression when said double stranded nucleic acid is introduced into a mammalian cell.
12. A method for reducing expression of a target KRAS gene in a mammalian cell comprising contacting a mammalian cell in vitro with an isolated dsNA of claim 1 in an amount sufficient to reduce expression of a target KRAS gene in said cell.
13. The method of claim 12 , wherein target KRAS gene expression is reduced by an amount (expressed by %) selected from the group consisting of at least 10%, at least 50% and at least 80-90%.
14. The method of claim 12 , wherein KRAS mRNA levels are reduced by an amount (expressed by %) of at least 90% at least 8 days after said cell is contacted with said dsNA.
15. The method of claim 12 , wherein KRAS mRNA levels are reduced by an amount (expressed by %) of at least 70% at least 10 days after said cell is contacted with said dsNA.
16. A method for reducing expression of a target KRAS gene in a mammal comprising administering an isolated dsNA of claim 1 to a mammal in an amount sufficient to reduce expression of a target KRAS gene in the mammal.
17. The method of claim 16 , wherein said isolated dsNA is administered at a dosage selected from the group consisting of 1 microgram to 5 milligrams per kilogram of said mammal per day, 100 micrograms to 0.5 milligrams per kilogram, and 0.001 to 0.25 milligrams per kilogram, 0.01 to 20 micrograms per kilogram.
18. The method of claim 16 , wherein said administering step comprises a mode selected from the group consisting of intravenous injection, intramuscular injection, intraperitoneal injection, infusion, subcutaneous injection, transdermal, aerosol, rectal, vaginal, topical, oral and inhaled delivery.
19. A method for selectively inhibiting the growth of a cell comprising contacting a cell with an amount of an isolated dsNA of claim 1 sufficient to inhibit the growth of the cell.
20. The method of claim 19 , wherein said cell is a tumor cell of a subject.
21. The method of claim 19 , wherein said cell is a tumor cell in vitro.
22. The method of claim 19 , wherein said cell is a human cell.
23. The method of claim 19 , wherein said cell is a pancreatic carcinoma cell.
24. An isolated mammalian cell containing the isolated dsNA of claim 1 .
25. A pharmaceutical composition comprising the isolated dsNA of claim 1 and a pharmaceutically acceptable carrier.
26. A kit comprising the isolated dsNA of claim 1 and instructions for its use.